Omeprazole Stada

Omeprazole, the active ingredient in Omeprazole Stada, is a proton‑pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults. GNH USA supplies Omeprazole Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole Stada is a proton‑pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related gastrointestinal conditions: - Gastro‑esophageal reflux disease (GERD): alleviates heartburn and promotes healing of the esophageal lining. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors. - Erosive esophagitis: facilitates mucosal healing in acid‑induced esophageal injury. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates.

Omeprazole Stada is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually transient. - Nausea: occasional mild upset. - Abdominal pain: mild cramping. - Flatulence: increased gas. - Constipation: occasional bowel habit change.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Acute interstitial nephritis: kidney inflammation. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Low magnesium levels: may cause muscle cramps or arrhythmia. - Fracture risk: long‑term use linked to reduced bone density.

When prescribing Omeprazole Stada, consider the following safety measures: - Assess renal function: adjust use in severe impairment. - Review liver status: use with caution in hepatic disease. - Evaluate need for long‑term therapy: monitor bone health. - Monitor for infections: be alert to signs of C. difficile. - Pregnancy and lactation: weigh benefits against potential risks. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Omeprazole Stada can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir: decreased antiviral absorption, may lead to treatment failure. - Ketoconazole: markedly reduced antifungal exposure.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, monitor coagulation. - Phenytoin: decreased serum levels, watch for seizure control. - Digoxin: modest rise in concentration, assess for toxicity.